David Soergel's most recent trade in Madrigal Pharmaceuticals Inc was a trade of 5,467 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharma Inc | David Soergel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 5,467 | 5,467 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | David Soergel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 4,374 | 11,919 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharma Inc | David Soergel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 12,839 | 12,839 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | David Soergel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 7,545 | 7,545 (0%) | 0% | 0 | Common Stock |